Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing

  • ACS Med Chem Lett. 2019 Oct 18;10(11):1537-1542. doi: 10.1021/acsmedchemlett.9b00360.
Timothy A Lewis  1 ,  Luc de Waal  1  2 ,  Xiaoyun Wu  1  2 ,  Willmen Youngsaye  1 ,  Antje Wengner  3 ,  Charlotte Kopitz  3 ,  Martin Lange  3 ,  Stefan Gradl  3 ,  Manuel Ellermann  3 ,  Philip Lienau  3 ,  Stuart L Schreiber  1 ,  Heidi Greulich  1  2 ,  Matthew Meyerson  1  2
Affiliations
  • 1. Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
  • 2. Dana-Farber Cancer Institute, Boston, Massachusetts 01255, United States.
  • 3. Bayer AG, Berlin, Germany.
PMID: 31749907 DOI: 10.1021/acsmedchemlett.9b00360
Abstract

6-(4-(Diethylamino)-3-nitrophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one, or DNMDP, potently and selectively inhibits phosphodiesterases 3A and 3B (PDE3A and PDE3B) and kills Cancer cells by inducing PDE3A/B interactions with SFLN12. The structure-activity relationship (SAR) of DNMDP analogs was evaluated using a phenotypic viability assay, resulting in several compounds with suitable pharmacokinetic properties for in vivo analysis. One of these compounds, BRD9500, was active in an SK-MEL-3 xenograft model of Cancer.

Products